Pfizer trialing video game designed to diagnose Alzheimer's

Pfizer ($PFE) is working with Akili Interactive Labs on a video game app designed to diagnose Alzheimer's. The game attempts to assess whether someone has Alzheimer's by evaluating how well they respond to distractions and interruptions. Pfizer is now trialing the system by having 100 healthy patients, some of whom have Alzheimer's-tied amyloid proteins in their brains, use the game. If successful, the game could become a biomarker or endpoint in future trials. Article

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.